Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma

Sponsor
Nanfang Hospital, Southern Medical University
Study ID
NCT04221516
Phase
PHASE2
Status
Unknown

Conditions

  • Nasopharyngeal Carcinoma
  • Oligometastasis
  • Radiotherapy

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab — DRUG
    Camrelizumab 200mg every 21 days (3 weeks) for up to 18 cycles, from 4 to 12 weeks after the completion of radiotherapy.

Study Details

The main purpose of this study is to see how well the experimental drug camrelizumab(SHR-1210) works in people with oligometastatic NPC who have already had locally radiotherapy for their disease. All patients will receive 200 mg of camrelizumab intravenously on Day 1 of each 21-day cycle. Patients will receive the study drug for up to 18 cycles.

Key Dates

Start date
Jan 1, 2020
Status verified
Jun 2023
Primary completion
Feb 1, 2024
Completion
Feb 1, 2024

Study Design

Enrollment
52 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Camrelizumab
    Camrelizumab 200mg every 21 days for up to 18 cycles, from 4 to 12 weeks after the completion of radiotherapy.

Primary Outcome Measure

Progression Free Survival [ Time Frame: 3 years ]

Central Contacts

Related Studies